Booz Allen launches AI-powered cybersecurity product suite at RSAC
Get Alerts BAH Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2%
Revenue Growth %: -3.8%
Join SI Premium – FREE
Booz Allen Hamilton (NYSE: BAH) unveiled its Vellox suite of AI-native cybersecurity products at the RSA Conference 2026 in San Francisco. The launch comes as the company's threat report shows cyberattack speeds have accelerated dramatically, with average breakout times dropping to under 30 minutes in 2025.
The Vellox product suite includes five tools designed to combat AI-powered cyber threats. Two products are currently available: Vellox Reverser for malware analysis and threat intelligence, and Vellox Ranger for detection engineering in limited preview. Three additional products are launching soon: Vellox Striker for security assessments, Vellox Navigator for compliance monitoring, and Vellox Responder for autonomous threat remediation.
According to Booz Allen's report "When Cyberattacks Happen at AI Speed," the fastest cyberattack cases in 2025 were measured in seconds, while compromising enterprise boundaries now takes minutes rather than the weeks or months previously required.
"Cybersecurity has become a race against time. Adversaries are operating at machine speed, and defending against them requires systems built for that reality," said Brad Medairy, executive vice president and leader of Booz Allen's national cyber business.
The McLean, Virginia-based company reported revenue of $12.0 billion for the 12 months ended March 31, 2025, and employs approximately 31,600 people globally as of December 31, 2025. Booz Allen serves federal, defense, and intelligence customers as well as Fortune 500 and Forbes Global 2000 companies.
The company is displaying the Vellox products at RSAC Booth S-0461 through March 26 at the Moscone Center.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- RBC Capital Starts Northview Residential REIT (NRR-U:CN) at Sector Perform
- Enanta Pharma loses appeal in Pfizer Paxlovid patent case
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share